← Back to Nuqta Atlas
Editorially curated · qa-danna-cohort
DANNA Cohort
Population-based type 1 diabetes registry combining autoantibodies, whole genomes, family recruitment, and longitudinal clinical records to build a MENA-specific genetic risk score.
01 / Project overview
What the record establishes.
- Geographic scope
- Qatar with MENA Arab representation
- Project type
- type 1 diabetes genomic registry and family cohort
- Research domain
- autoimmunity, diabetes genomics, and risk prediction
- Years
- Not stated
- Lifecycle status
- active
- Status basis
- Sidra described DANNA on 22 July 2025 as an ongoing foundational registry supporting an upcoming national type 1 diabetes screening program.
- Status evidence date
- 2025-07-22
- Scale
- All participants receive whole-genome sequencing and linkage to comprehensive electronic health records; public enrollment count is not stated.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- Sidra Medicine
- Partner organizations
- Hamad Medical Corporation
- Organism / population
- Children and adults with type 1 diabetes and their family members
03 / Data and access
What exists and how it can be reached.
Data types
- whole-genome sequencing
- autoantibodies
- electronic health records
- family data
- genetic risk scores
Data access
Controlled Sidra/HMC research access.
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Named, whole-genome-sequenced national disease/family registry with a translational screening output.
Editorial note
Nested under Sidra's Genome 2 Cure/Metabolic and Mendelian program; no public sample total yet.
Sources
- primary record source Verified 2026-08-15
Release v0.2.0